| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 52 | 2021 | 262 | 9.630 |
Why?
|
| Middle Aged | 146 | 2022 | 7911 | 3.020 |
Why?
|
| Humans | 204 | 2023 | 17611 | 2.910 |
Why?
|
| Urinary Incontinence | 20 | 2020 | 28 | 2.900 |
Why?
|
| Aged | 125 | 2022 | 6095 | 2.820 |
Why?
|
| Genetic Predisposition to Disease | 20 | 2022 | 368 | 2.640 |
Why?
|
| Male | 135 | 2023 | 10008 | 2.610 |
Why?
|
| California | 66 | 2022 | 2284 | 2.230 |
Why?
|
| European Continental Ancestry Group | 30 | 2020 | 529 | 2.150 |
Why?
|
| Cohort Studies | 63 | 2022 | 2570 | 2.050 |
Why?
|
| Quality of Life | 15 | 2022 | 507 | 1.860 |
Why?
|
| Decision Making | 9 | 2019 | 183 | 1.850 |
Why?
|
| Genome-Wide Association Study | 17 | 2021 | 243 | 1.780 |
Why?
|
| Risk Factors | 62 | 2023 | 3325 | 1.730 |
Why?
|
| Pancreatic Neoplasms | 10 | 2020 | 67 | 1.720 |
Why?
|
| Parkinson Disease | 10 | 2011 | 15 | 1.650 |
Why?
|
| Adult | 87 | 2022 | 7598 | 1.650 |
Why?
|
| Female | 103 | 2022 | 12608 | 1.590 |
Why?
|
| Continental Population Groups | 14 | 2021 | 302 | 1.570 |
Why?
|
| Surveys and Questionnaires | 36 | 2020 | 1309 | 1.500 |
Why?
|
| Sexual Behavior | 11 | 2017 | 124 | 1.480 |
Why?
|
| Polymorphism, Single Nucleotide | 17 | 2020 | 373 | 1.450 |
Why?
|
| Androgen Antagonists | 5 | 2017 | 17 | 1.300 |
Why?
|
| Case-Control Studies | 37 | 2020 | 1115 | 1.270 |
Why?
|
| Odds Ratio | 32 | 2021 | 671 | 1.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2023 | 748 | 1.240 |
Why?
|
| Ethnic Groups | 13 | 2020 | 485 | 1.220 |
Why?
|
| Erectile Dysfunction | 6 | 2019 | 24 | 1.220 |
Why?
|
| Pancreatitis, Chronic | 4 | 2023 | 19 | 1.210 |
Why?
|
| Aging | 10 | 2016 | 161 | 1.210 |
Why?
|
| African Americans | 14 | 2020 | 472 | 1.200 |
Why?
|
| Prostate | 4 | 2019 | 28 | 1.190 |
Why?
|
| Lower Urinary Tract Symptoms | 5 | 2014 | 13 | 1.160 |
Why?
|
| Hispanic Americans | 10 | 2020 | 404 | 1.110 |
Why?
|
| Genomics | 5 | 2020 | 55 | 1.110 |
Why?
|
| Diabetes Mellitus | 8 | 2018 | 487 | 1.100 |
Why?
|
| Cross-Sectional Studies | 26 | 2023 | 1322 | 1.020 |
Why?
|
| Smoking | 12 | 2015 | 483 | 1.000 |
Why?
|
| Prospective Studies | 22 | 2020 | 1267 | 1.000 |
Why?
|
| Logistic Models | 25 | 2021 | 926 | 1.000 |
Why?
|
| Liver Neoplasms | 3 | 2020 | 40 | 0.980 |
Why?
|
| Risk Assessment | 20 | 2020 | 1097 | 0.920 |
Why?
|
| Watchful Waiting | 3 | 2019 | 18 | 0.900 |
Why?
|
| Health Status | 9 | 2015 | 298 | 0.890 |
Why?
|
| Prostatectomy | 7 | 2020 | 75 | 0.880 |
Why?
|
| Incidence | 25 | 2020 | 1255 | 0.850 |
Why?
|
| Prevalence | 21 | 2018 | 884 | 0.840 |
Why?
|
| Prostatic Hyperplasia | 4 | 2018 | 24 | 0.840 |
Why?
|
| Aged, 80 and over | 29 | 2020 | 1900 | 0.820 |
Why?
|
| Multifactorial Inheritance | 2 | 2020 | 20 | 0.820 |
Why?
|
| Prostate-Specific Antigen | 8 | 2017 | 75 | 0.800 |
Why?
|
| Retrospective Studies | 23 | 2020 | 2447 | 0.800 |
Why?
|
| Health Maintenance Organizations | 11 | 2012 | 417 | 0.790 |
Why?
|
| Population Surveillance | 4 | 2017 | 263 | 0.790 |
Why?
|
| Diabetes Complications | 9 | 2016 | 114 | 0.790 |
Why?
|
| Multiple Sclerosis | 4 | 2020 | 97 | 0.760 |
Why?
|
| Body Mass Index | 10 | 2019 | 958 | 0.760 |
Why?
|
| Lung Neoplasms | 5 | 2021 | 255 | 0.760 |
Why?
|
| Breast Neoplasms, Male | 4 | 2015 | 9 | 0.750 |
Why?
|
| Environmental Pollutants | 2 | 2020 | 46 | 0.750 |
Why?
|
| Neoplasms | 7 | 2022 | 438 | 0.740 |
Why?
|
| Genetic Loci | 5 | 2021 | 55 | 0.740 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2020 | 11 | 0.710 |
Why?
|
| Sexual Dysfunction, Physiological | 6 | 2014 | 9 | 0.710 |
Why?
|
| Urinary Incontinence, Stress | 4 | 2015 | 6 | 0.710 |
Why?
|
| Restless Legs Syndrome | 3 | 2016 | 4 | 0.700 |
Why?
|
| Proportional Hazards Models | 15 | 2018 | 709 | 0.700 |
Why?
|
| Breast Feeding | 5 | 2020 | 133 | 0.690 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2018 | 20 | 0.650 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2018 | 65 | 0.640 |
Why?
|
| Salvage Therapy | 3 | 2020 | 17 | 0.640 |
Why?
|
| Risk | 16 | 2019 | 516 | 0.630 |
Why?
|
| Postmenopause | 3 | 2020 | 241 | 0.630 |
Why?
|
| African Continental Ancestry Group | 10 | 2017 | 162 | 0.630 |
Why?
|
| Health Status Disparities | 3 | 2020 | 146 | 0.620 |
Why?
|
| Health | 3 | 2015 | 33 | 0.620 |
Why?
|
| Cardiovascular Diseases | 5 | 2019 | 598 | 0.610 |
Why?
|
| Asthma | 5 | 2011 | 385 | 0.610 |
Why?
|
| Follow-Up Studies | 14 | 2018 | 1210 | 0.610 |
Why?
|
| Gonadotropin-Releasing Hormone | 4 | 2017 | 10 | 0.600 |
Why?
|
| Research Design | 3 | 2018 | 374 | 0.600 |
Why?
|
| Nocturia | 2 | 2020 | 4 | 0.600 |
Why?
|
| 5-alpha Reductase Inhibitors | 2 | 2018 | 7 | 0.590 |
Why?
|
| Time Factors | 13 | 2020 | 1086 | 0.590 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2015 | 56 | 0.580 |
Why?
|
| Multivariate Analysis | 12 | 2020 | 568 | 0.580 |
Why?
|
| Uterine Prolapse | 5 | 2009 | 5 | 0.560 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2019 | 171 | 0.560 |
Why?
|
| Transcriptome | 3 | 2020 | 22 | 0.550 |
Why?
|
| Genetic Variation | 3 | 2019 | 77 | 0.550 |
Why?
|
| Biomarkers, Tumor | 5 | 2021 | 142 | 0.550 |
Why?
|
| Neoplasm Staging | 9 | 2016 | 325 | 0.540 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2020 | 26 | 0.540 |
Why?
|
| Urination Disorders | 6 | 2012 | 10 | 0.540 |
Why?
|
| Patient Preference | 2 | 2017 | 48 | 0.540 |
Why?
|
| Pregnancy | 13 | 2021 | 1494 | 0.540 |
Why?
|
| Physicians | 2 | 2017 | 137 | 0.520 |
Why?
|
| Vaginal Diseases | 2 | 2016 | 6 | 0.510 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 34 | 0.510 |
Why?
|
| Asian Continental Ancestry Group | 5 | 2017 | 90 | 0.510 |
Why?
|
| Disease Progression | 8 | 2019 | 264 | 0.500 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 9 | 0.500 |
Why?
|
| Torticollis | 2 | 2019 | 3 | 0.500 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2012 | 4 | 0.490 |
Why?
|
| Neoplasm Grading | 4 | 2020 | 48 | 0.480 |
Why?
|
| Asian Americans | 7 | 2013 | 176 | 0.480 |
Why?
|
| Marijuana Smoking | 2 | 2015 | 52 | 0.460 |
Why?
|
| Electronic Health Records | 2 | 2022 | 681 | 0.460 |
Why?
|
| Urinary Incontinence, Urge | 2 | 2015 | 3 | 0.450 |
Why?
|
| Pregnancy Trimesters | 2 | 2016 | 30 | 0.450 |
Why?
|
| Age Factors | 14 | 2016 | 917 | 0.450 |
Why?
|
| Air Pollutants | 3 | 2018 | 52 | 0.430 |
Why?
|
| Obesity | 5 | 2023 | 837 | 0.420 |
Why?
|
| Blood Glucose | 3 | 2010 | 341 | 0.420 |
Why?
|
| Air Pollution | 2 | 2018 | 42 | 0.420 |
Why?
|
| Health Behavior | 3 | 2012 | 359 | 0.420 |
Why?
|
| Adenocarcinoma | 3 | 2018 | 172 | 0.420 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2022 | 15 | 0.420 |
Why?
|
| Fecal Incontinence | 4 | 2012 | 5 | 0.420 |
Why?
|
| Postpartum Period | 3 | 2020 | 94 | 0.420 |
Why?
|
| Hysterectomy | 8 | 2015 | 29 | 0.410 |
Why?
|
| Polymerase Chain Reaction | 2 | 2012 | 49 | 0.410 |
Why?
|
| Computational Biology | 3 | 2015 | 27 | 0.410 |
Why?
|
| Trees | 1 | 2022 | 3 | 0.410 |
Why?
|
| Men's Health | 5 | 2019 | 20 | 0.410 |
Why?
|
| Blood Specimen Collection | 2 | 2018 | 7 | 0.400 |
Why?
|
| Biological Specimen Banks | 1 | 2022 | 12 | 0.400 |
Why?
|
| Genotype | 8 | 2021 | 227 | 0.400 |
Why?
|
| Young Adult | 11 | 2022 | 2427 | 0.400 |
Why?
|
| United States | 18 | 2022 | 3956 | 0.400 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2017 | 32 | 0.400 |
Why?
|
| Longitudinal Studies | 7 | 2022 | 710 | 0.390 |
Why?
|
| International Cooperation | 3 | 2015 | 17 | 0.390 |
Why?
|
| Life Style | 5 | 2019 | 332 | 0.390 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2012 | 50 | 0.390 |
Why?
|
| Vehicle Emissions | 3 | 2018 | 23 | 0.390 |
Why?
|
| Glycated Hemoglobin A | 3 | 2017 | 216 | 0.390 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2018 | 9 | 0.380 |
Why?
|
| Self Report | 2 | 2015 | 251 | 0.380 |
Why?
|
| Parks, Recreational | 1 | 2022 | 38 | 0.380 |
Why?
|
| Adolescent | 18 | 2022 | 3651 | 0.380 |
Why?
|
| Chronic Disease | 3 | 2017 | 428 | 0.380 |
Why?
|
| Complementary Therapies | 2 | 2012 | 46 | 0.380 |
Why?
|
| Legislation, Drug | 1 | 2021 | 10 | 0.370 |
Why?
|
| Treatment Outcome | 10 | 2017 | 1259 | 0.370 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2010 | 375 | 0.370 |
Why?
|
| Cancer Survivors | 1 | 2022 | 83 | 0.370 |
Why?
|
| Pneumococcal Vaccines | 2 | 2012 | 64 | 0.370 |
Why?
|
| Comorbidity | 11 | 2015 | 594 | 0.360 |
Why?
|
| Marijuana Use | 1 | 2021 | 36 | 0.360 |
Why?
|
| Quality Improvement | 1 | 2022 | 189 | 0.350 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2013 | 121 | 0.350 |
Why?
|
| Molecular Epidemiology | 4 | 2021 | 44 | 0.340 |
Why?
|
| Health Surveys | 7 | 2014 | 260 | 0.340 |
Why?
|
| Pelvic Floor | 3 | 2009 | 3 | 0.340 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 19 | 0.340 |
Why?
|
| Intimate Partner Violence | 1 | 2020 | 11 | 0.340 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2017 | 63 | 0.340 |
Why?
|
| Labor, Obstetric | 2 | 2011 | 5 | 0.340 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2020 | 58 | 0.330 |
Why?
|
| Colorectal Neoplasms | 3 | 2013 | 613 | 0.330 |
Why?
|
| Pregnancy Complications | 2 | 2020 | 196 | 0.330 |
Why?
|
| Depression | 5 | 2017 | 502 | 0.330 |
Why?
|
| Body Weight | 2 | 2019 | 219 | 0.330 |
Why?
|
| Pneumonia | 1 | 2009 | 51 | 0.330 |
Why?
|
| Cannabis | 1 | 2021 | 78 | 0.330 |
Why?
|
| Specimen Handling | 1 | 2018 | 20 | 0.320 |
Why?
|
| Pregnancy, Ectopic | 2 | 2011 | 6 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 244 | 0.310 |
Why?
|
| Translational Medical Research | 1 | 2018 | 35 | 0.310 |
Why?
|
| Pelvic Organ Prolapse | 3 | 2017 | 3 | 0.310 |
Why?
|
| Hypoglycemic Agents | 5 | 2015 | 268 | 0.310 |
Why?
|
| Histone Demethylases | 1 | 2018 | 3 | 0.310 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2018 | 3 | 0.310 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 9 | 0.310 |
Why?
|
| Chromosomes, Human | 1 | 2018 | 2 | 0.300 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2018 | 14 | 0.300 |
Why?
|
| Genetic Markers | 1 | 2018 | 25 | 0.300 |
Why?
|
| Medical Records | 2 | 2011 | 100 | 0.300 |
Why?
|
| Macular Degeneration | 1 | 2018 | 19 | 0.300 |
Why?
|
| Recurrence | 7 | 2020 | 186 | 0.300 |
Why?
|
| Alleles | 6 | 2019 | 84 | 0.300 |
Why?
|
| Trans-Activators | 2 | 2018 | 8 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2014 | 3 | 0.300 |
Why?
|
| Prognosis | 6 | 2023 | 606 | 0.290 |
Why?
|
| Social Class | 4 | 2017 | 120 | 0.290 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 197 | 0.290 |
Why?
|
| Patient Education as Topic | 2 | 2017 | 211 | 0.290 |
Why?
|
| Heart Failure | 3 | 2017 | 396 | 0.290 |
Why?
|
| Urologic Diseases | 2 | 2009 | 6 | 0.290 |
Why?
|
| Physician's Role | 1 | 2017 | 31 | 0.280 |
Why?
|
| Perception | 1 | 2017 | 58 | 0.280 |
Why?
|
| Prenatal Care | 2 | 2016 | 128 | 0.280 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2016 | 4 | 0.280 |
Why?
|
| Sildenafil Citrate | 1 | 2016 | 4 | 0.280 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2006 | 99 | 0.270 |
Why?
|
| Prepaid Health Plans | 1 | 2006 | 20 | 0.270 |
Why?
|
| Patient Satisfaction | 3 | 2012 | 211 | 0.270 |
Why?
|
| Maternal Exposure | 1 | 2016 | 60 | 0.270 |
Why?
|
| Melanoma | 1 | 2016 | 35 | 0.270 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2016 | 382 | 0.260 |
Why?
|
| Sexual Dysfunctions, Psychological | 3 | 2016 | 4 | 0.260 |
Why?
|
| Overweight | 3 | 2019 | 269 | 0.260 |
Why?
|
| Delivery, Obstetric | 2 | 2013 | 16 | 0.260 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2011 | 54 | 0.260 |
Why?
|
| Forecasting | 1 | 2016 | 75 | 0.260 |
Why?
|
| Registries | 5 | 2022 | 471 | 0.260 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2016 | 8 | 0.260 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 212 | 0.250 |
Why?
|
| Telomere | 1 | 2015 | 19 | 0.250 |
Why?
|
| Genome, Human | 2 | 2012 | 32 | 0.250 |
Why?
|
| Phenotype | 3 | 2022 | 149 | 0.250 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 16 | 0.250 |
Why?
|
| Parity | 2 | 2013 | 74 | 0.240 |
Why?
|
| Women | 1 | 2014 | 12 | 0.240 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2016 | 160 | 0.240 |
Why?
|
| Mass Screening | 3 | 2009 | 661 | 0.240 |
Why?
|
| Glioma | 1 | 2004 | 5 | 0.240 |
Why?
|
| Brain Neoplasms | 1 | 2004 | 15 | 0.230 |
Why?
|
| Poverty | 1 | 2015 | 166 | 0.230 |
Why?
|
| Managed Care Programs | 3 | 2016 | 325 | 0.230 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 330 | 0.230 |
Why?
|
| Acute Disease | 3 | 2023 | 142 | 0.230 |
Why?
|
| Myocardial Infarction | 3 | 2015 | 238 | 0.230 |
Why?
|
| Health Care Costs | 3 | 2022 | 228 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2012 | 129 | 0.230 |
Why?
|
| Insulin, Long-Acting | 1 | 2013 | 11 | 0.230 |
Why?
|
| Motor Activity | 1 | 2015 | 212 | 0.220 |
Why?
|
| Socioeconomic Factors | 9 | 2013 | 630 | 0.220 |
Why?
|
| Magnesium Oxide | 1 | 2003 | 1 | 0.220 |
Why?
|
| Interviews as Topic | 5 | 2018 | 305 | 0.220 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 3 | 0.220 |
Why?
|
| Lactation | 2 | 2010 | 52 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 51 | 0.220 |
Why?
|
| Hypertension | 2 | 2015 | 500 | 0.220 |
Why?
|
| Thiazolidinediones | 2 | 2015 | 52 | 0.220 |
Why?
|
| Migraine Disorders | 1 | 2003 | 16 | 0.210 |
Why?
|
| Condylomata Acuminata | 3 | 1998 | 23 | 0.210 |
Why?
|
| Confidence Intervals | 6 | 2013 | 237 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2017 | 3 | 0.210 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 3 | 0.210 |
Why?
|
| Models, Statistical | 3 | 2023 | 177 | 0.210 |
Why?
|
| Cause of Death | 5 | 2020 | 181 | 0.210 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2009 | 7 | 0.210 |
Why?
|
| Gene Expression | 3 | 2020 | 23 | 0.210 |
Why?
|
| Residence Characteristics | 2 | 2018 | 248 | 0.210 |
Why?
|
| HIV Infections | 2 | 2014 | 694 | 0.210 |
Why?
|
| Europe | 2 | 2020 | 42 | 0.210 |
Why?
|
| Defecation | 2 | 2012 | 5 | 0.210 |
Why?
|
| Pergolide | 1 | 2012 | 1 | 0.200 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2002 | 2 | 0.200 |
Why?
|
| Pneumococcal Infections | 1 | 2012 | 42 | 0.200 |
Why?
|
| Dopamine Agonists | 1 | 2012 | 3 | 0.200 |
Why?
|
| Prostatitis | 2 | 2011 | 5 | 0.200 |
Why?
|
| Heart Valve Diseases | 1 | 2012 | 20 | 0.200 |
Why?
|
| ABO Blood-Group System | 2 | 2013 | 2 | 0.200 |
Why?
|
| Reproducibility of Results | 5 | 2015 | 381 | 0.200 |
Why?
|
| Polypharmacy | 1 | 2011 | 13 | 0.200 |
Why?
|
| Bronchodilator Agents | 1 | 2011 | 21 | 0.200 |
Why?
|
| Stroke | 2 | 2015 | 311 | 0.200 |
Why?
|
| Parturition | 1 | 2011 | 9 | 0.190 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2011 | 1 | 0.190 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2011 | 2 | 0.190 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 108 | 0.190 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 62 | 0.190 |
Why?
|
| Neuroprotective Agents | 1 | 2011 | 1 | 0.190 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2011 | 1 | 0.190 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2011 | 2 | 0.190 |
Why?
|
| Direct Service Costs | 2 | 2001 | 8 | 0.190 |
Why?
|
| Caffeine | 1 | 2011 | 18 | 0.190 |
Why?
|
| Estrogens | 2 | 2015 | 61 | 0.180 |
Why?
|
| Carcinogenesis | 1 | 2020 | 9 | 0.180 |
Why?
|
| Vitamin D Deficiency | 1 | 2010 | 21 | 0.180 |
Why?
|
| Norway | 1 | 2020 | 4 | 0.180 |
Why?
|
| Veterans | 1 | 2012 | 141 | 0.180 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2020 | 22 | 0.180 |
Why?
|
| Activities of Daily Living | 3 | 2016 | 85 | 0.180 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 26 | 0.180 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 23 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2010 | 2 | 0.180 |
Why?
|
| Preventive Health Services | 1 | 2012 | 159 | 0.180 |
Why?
|
| Educational Status | 6 | 2009 | 200 | 0.180 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 20 | 0.180 |
Why?
|
| Antidepressive Agents | 1 | 2011 | 155 | 0.180 |
Why?
|
| Patient Admission | 2 | 2002 | 72 | 0.180 |
Why?
|
| Self Disclosure | 2 | 2007 | 22 | 0.170 |
Why?
|
| Interferon-gamma | 1 | 2010 | 8 | 0.170 |
Why?
|
| Immune Tolerance | 1 | 2010 | 6 | 0.170 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 8 | 0.170 |
Why?
|
| Carcinoma | 1 | 2010 | 22 | 0.170 |
Why?
|
| Wine | 1 | 2010 | 18 | 0.170 |
Why?
|
| Family | 1 | 2010 | 111 | 0.170 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2010 | 16 | 0.170 |
Why?
|
| Urinary Bladder Diseases | 3 | 2009 | 5 | 0.170 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 949 | 0.170 |
Why?
|
| Serine Endopeptidases | 1 | 2019 | 5 | 0.170 |
Why?
|
| Databases, Genetic | 2 | 2020 | 9 | 0.170 |
Why?
|
| Models, Genetic | 1 | 2019 | 23 | 0.170 |
Why?
|
| Family Characteristics | 1 | 2009 | 54 | 0.170 |
Why?
|
| Access to Information | 1 | 2009 | 13 | 0.170 |
Why?
|
| Puerperal Disorders | 1 | 2009 | 9 | 0.170 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 31 | 0.170 |
Why?
|
| Patient Selection | 1 | 2010 | 190 | 0.160 |
Why?
|
| Occupational Diseases | 3 | 1993 | 41 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 351 | 0.160 |
Why?
|
| Repressor Proteins | 2 | 2019 | 13 | 0.160 |
Why?
|
| Hospitalization | 4 | 2006 | 797 | 0.160 |
Why?
|
| Linkage Disequilibrium | 3 | 2010 | 30 | 0.160 |
Why?
|
| Survival Analysis | 5 | 2013 | 215 | 0.150 |
Why?
|
| Constipation | 1 | 2008 | 4 | 0.150 |
Why?
|
| Biomarkers | 4 | 2018 | 301 | 0.150 |
Why?
|
| Sex Factors | 6 | 2020 | 643 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 129 | 0.150 |
Why?
|
| Personal Satisfaction | 3 | 2014 | 11 | 0.150 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 130 | 0.150 |
Why?
|
| Environment | 2 | 2016 | 51 | 0.150 |
Why?
|
| Geography, Medical | 1 | 2017 | 4 | 0.150 |
Why?
|
| Palpation | 2 | 2005 | 10 | 0.150 |
Why?
|
| ROC Curve | 3 | 2018 | 77 | 0.150 |
Why?
|
| Gene Frequency | 4 | 2017 | 43 | 0.140 |
Why?
|
| Mental Recall | 1 | 2007 | 31 | 0.140 |
Why?
|
| Tobacco Use Disorder | 1 | 2007 | 49 | 0.140 |
Why?
|
| Carbon Monoxide | 2 | 2016 | 13 | 0.140 |
Why?
|
| Biomedical Research | 2 | 2018 | 86 | 0.140 |
Why?
|
| Nitrogen Dioxide | 2 | 2016 | 13 | 0.140 |
Why?
|
| Biopsy | 2 | 2017 | 74 | 0.140 |
Why?
|
| Health Care Surveys | 3 | 2012 | 230 | 0.140 |
Why?
|
| Reproductive History | 1 | 2006 | 17 | 0.140 |
Why?
|
| Age of Onset | 3 | 2009 | 79 | 0.140 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 145 | 0.130 |
Why?
|
| Alcohol Drinking | 3 | 2014 | 368 | 0.130 |
Why?
|
| Anxiety | 2 | 2018 | 150 | 0.130 |
Why?
|
| Infant, Newborn | 5 | 2016 | 844 | 0.130 |
Why?
|
| Emotions | 2 | 2016 | 34 | 0.130 |
Why?
|
| Databases, Factual | 3 | 2012 | 309 | 0.130 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 26 | 0.130 |
Why?
|
| Methotrexate | 1 | 2005 | 6 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 18 | 0.130 |
Why?
|
| Self Concept | 2 | 2016 | 39 | 0.120 |
Why?
|
| Abortion, Induced | 1 | 2005 | 18 | 0.120 |
Why?
|
| Environmental Exposure | 1 | 2016 | 116 | 0.120 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 454 | 0.120 |
Why?
|
| Quantitative Trait Loci | 2 | 2020 | 36 | 0.120 |
Why?
|
| Telomerase | 1 | 2014 | 4 | 0.120 |
Why?
|
| Ambulatory Care | 2 | 2006 | 244 | 0.120 |
Why?
|
| Membrane Proteins | 1 | 2014 | 38 | 0.120 |
Why?
|
| Occupational Exposure | 2 | 1996 | 67 | 0.120 |
Why?
|
| Child, Preschool | 4 | 2016 | 1409 | 0.120 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 154 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 78 | 0.110 |
Why?
|
| Women's Health | 3 | 2009 | 200 | 0.110 |
Why?
|
| Oxidants, Photochemical | 1 | 2002 | 2 | 0.110 |
Why?
|
| Emergency Service, Hospital | 2 | 2006 | 358 | 0.110 |
Why?
|
| Ozone | 1 | 2002 | 11 | 0.110 |
Why?
|
| Whole Exome Sequencing | 1 | 2022 | 8 | 0.110 |
Why?
|
| Myocardial Ischemia | 1 | 2002 | 24 | 0.110 |
Why?
|
| Exome | 1 | 2022 | 21 | 0.110 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2018 | 228 | 0.110 |
Why?
|
| Meta-Analysis as Topic | 2 | 2007 | 32 | 0.110 |
Why?
|
| Reproduction | 2 | 2014 | 12 | 0.100 |
Why?
|
| Haplotypes | 2 | 2015 | 34 | 0.100 |
Why?
|
| Patient Care Planning | 1 | 2002 | 52 | 0.100 |
Why?
|
| Epidemiologic Studies | 3 | 2012 | 29 | 0.100 |
Why?
|
| Abdominal Pain | 1 | 2022 | 15 | 0.100 |
Why?
|
| Libido | 2 | 2014 | 3 | 0.100 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2002 | 4 | 0.100 |
Why?
|
| Sigmoidoscopy | 2 | 2007 | 65 | 0.100 |
Why?
|
| Rectocele | 1 | 2001 | 1 | 0.100 |
Why?
|
| Homosexuality, Male | 1 | 2011 | 38 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 4 | 0.100 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 154 | 0.090 |
Why?
|
| Oceanic Ancestry Group | 1 | 2020 | 33 | 0.090 |
Why?
|
| Testicular Neoplasms | 2 | 1991 | 11 | 0.090 |
Why?
|
| Infertility, Male | 1 | 2010 | 3 | 0.090 |
Why?
|
| Hair | 1 | 2000 | 7 | 0.090 |
Why?
|
| Face | 1 | 2000 | 5 | 0.090 |
Why?
|
| Insulin | 2 | 2013 | 205 | 0.090 |
Why?
|
| Analysis of Variance | 3 | 2012 | 159 | 0.090 |
Why?
|
| Insurance, Health | 1 | 2022 | 181 | 0.090 |
Why?
|
| Body Constitution | 1 | 2000 | 39 | 0.090 |
Why?
|
| Multiphasic Screening | 2 | 2016 | 8 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 20 | 0.090 |
Why?
|
| Diagnosis-Related Groups | 1 | 2000 | 24 | 0.090 |
Why?
|
| Interpersonal Relations | 1 | 2020 | 42 | 0.090 |
Why?
|
| Child | 5 | 2006 | 2474 | 0.080 |
Why?
|
| Cholesterol | 1 | 2019 | 106 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2019 | 4 | 0.080 |
Why?
|
| Internet | 2 | 2017 | 231 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2003 | 155 | 0.080 |
Why?
|
| Triglycerides | 1 | 2019 | 86 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 9 | 0.080 |
Why?
|
| Melanocortins | 1 | 2018 | 2 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2018 | 3 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 15 | 0.080 |
Why?
|
| Sexual Partners | 2 | 2013 | 37 | 0.080 |
Why?
|
| Infant | 3 | 2016 | 1171 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2018 | 38 | 0.080 |
Why?
|
| Age Distribution | 3 | 2011 | 246 | 0.080 |
Why?
|
| Genital Diseases, Male | 1 | 1998 | 2 | 0.080 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 47 | 0.080 |
Why?
|
| Leptin | 1 | 2018 | 29 | 0.080 |
Why?
|
| Genital Diseases, Female | 1 | 1998 | 9 | 0.080 |
Why?
|
| Geographic Mapping | 1 | 2018 | 4 | 0.080 |
Why?
|
| Epidemiologic Methods | 2 | 2016 | 81 | 0.080 |
Why?
|
| Hydrazines | 1 | 2018 | 2 | 0.080 |
Why?
|
| Cell Survival | 1 | 2018 | 7 | 0.080 |
Why?
|
| Conservative Treatment | 1 | 2018 | 1 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2018 | 14 | 0.080 |
Why?
|
| Tensins | 1 | 2018 | 1 | 0.080 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2018 | 2 | 0.080 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2018 | 4 | 0.080 |
Why?
|
| Cities | 1 | 2018 | 29 | 0.080 |
Why?
|
| Proteins | 1 | 2018 | 16 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 91 | 0.080 |
Why?
|
| Hysterectomy, Vaginal | 1 | 1998 | 1 | 0.080 |
Why?
|
| SEER Program | 2 | 2014 | 91 | 0.080 |
Why?
|
| Women's Health Services | 1 | 1998 | 20 | 0.080 |
Why?
|
| Aspartame | 2 | 1994 | 2 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 27 | 0.070 |
Why?
|
| Leuprolide | 1 | 2017 | 2 | 0.070 |
Why?
|
| Goserelin | 1 | 2017 | 2 | 0.070 |
Why?
|
| Imidazolidines | 1 | 2017 | 2 | 0.070 |
Why?
|
| Flutamide | 1 | 2017 | 3 | 0.070 |
Why?
|
| Anilides | 1 | 2017 | 3 | 0.070 |
Why?
|
| Tosyl Compounds | 1 | 2017 | 3 | 0.070 |
Why?
|
| Headache | 2 | 1994 | 14 | 0.070 |
Why?
|
| Nitriles | 1 | 2017 | 7 | 0.070 |
Why?
|
| Conflict (Psychology) | 1 | 2017 | 7 | 0.070 |
Why?
|
| Uncertainty | 1 | 2017 | 7 | 0.070 |
Why?
|
| Insurance Carriers | 1 | 2007 | 6 | 0.070 |
Why?
|
| Organizations, Nonprofit | 1 | 2007 | 11 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2018 | 114 | 0.070 |
Why?
|
| Laparoscopy | 1 | 1998 | 48 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2007 | 304 | 0.070 |
Why?
|
| Radiation Oncology | 1 | 2017 | 2 | 0.070 |
Why?
|
| Urology | 1 | 2017 | 5 | 0.070 |
Why?
|
| Information Seeking Behavior | 1 | 2017 | 10 | 0.070 |
Why?
|
| Occupational Health Nursing | 2 | 1985 | 2 | 0.070 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2016 | 2 | 0.070 |
Why?
|
| Substance-Related Disorders | 1 | 2011 | 434 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 15 | 0.070 |
Why?
|
| Denmark | 1 | 2016 | 18 | 0.070 |
Why?
|
| Causality | 1 | 2016 | 40 | 0.070 |
Why?
|
| Lead Poisoning | 1 | 1996 | 3 | 0.070 |
Why?
|
| Paternal Exposure | 1 | 1996 | 5 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 88 | 0.070 |
Why?
|
| Monte Carlo Method | 2 | 2011 | 15 | 0.070 |
Why?
|
| Body Image | 1 | 2016 | 21 | 0.070 |
Why?
|
| Arthritis | 1 | 2015 | 5 | 0.060 |
Why?
|
| Exercise Therapy | 2 | 2006 | 71 | 0.060 |
Why?
|
| Length of Stay | 3 | 2002 | 181 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 9 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2006 | 109 | 0.060 |
Why?
|
| Principal Component Analysis | 1 | 2015 | 23 | 0.060 |
Why?
|
| Angina Pectoris | 1 | 2015 | 16 | 0.060 |
Why?
|
| Automation | 1 | 2015 | 24 | 0.060 |
Why?
|
| Government Regulation | 1 | 1985 | 8 | 0.060 |
Why?
|
| Androgens | 1 | 2015 | 12 | 0.060 |
Why?
|
| Truth Disclosure | 1 | 1985 | 15 | 0.060 |
Why?
|
| Pedigree | 1 | 2015 | 60 | 0.060 |
Why?
|
| Hormones | 1 | 2015 | 14 | 0.060 |
Why?
|
| Estradiol | 1 | 2015 | 23 | 0.060 |
Why?
|
| Phylogeny | 1 | 2015 | 14 | 0.060 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 18 | 0.060 |
Why?
|
| Administration, Intravaginal | 1 | 2015 | 2 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2015 | 69 | 0.060 |
Why?
|
| Mobility Limitation | 1 | 2015 | 16 | 0.060 |
Why?
|
| Orgasm | 1 | 2014 | 1 | 0.060 |
Why?
|
| Hot Flashes | 1 | 2015 | 39 | 0.060 |
Why?
|
| Psychometrics | 1 | 2015 | 121 | 0.060 |
Why?
|
| Health Services Research | 2 | 2009 | 231 | 0.060 |
Why?
|
| Morbidity | 1 | 2014 | 59 | 0.060 |
Why?
|
| Behavior | 1 | 2004 | 18 | 0.060 |
Why?
|
| Orchiectomy | 1 | 2014 | 6 | 0.060 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2014 | 8 | 0.060 |
Why?
|
| Michigan | 1 | 2014 | 26 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 13 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 134 | 0.060 |
Why?
|
| Algorithms | 2 | 2011 | 233 | 0.060 |
Why?
|
| Insulin Glargine | 1 | 2013 | 9 | 0.060 |
Why?
|
| Washington | 4 | 1998 | 374 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2007 | 190 | 0.060 |
Why?
|
| Cesarean Section | 1 | 2013 | 30 | 0.060 |
Why?
|
| Binomial Distribution | 1 | 1993 | 2 | 0.060 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2013 | 3 | 0.060 |
Why?
|
| Family Health | 1 | 2013 | 44 | 0.060 |
Why?
|
| Patient Dropouts | 1 | 1993 | 22 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 44 | 0.050 |
Why?
|
| Poisson Distribution | 1 | 1993 | 88 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2003 | 85 | 0.050 |
Why?
|
| Air Pollutants, Occupational | 1 | 1993 | 16 | 0.050 |
Why?
|
| Thyroid Hormones | 1 | 2003 | 7 | 0.050 |
Why?
|
| Flatulence | 1 | 2012 | 1 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 29 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 70 | 0.050 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2012 | 1 | 0.050 |
Why?
|
| Potassium Channels | 1 | 2012 | 1 | 0.050 |
Why?
|
| Hip Fractures | 1 | 2003 | 67 | 0.050 |
Why?
|
| Forced Expiratory Volume | 1 | 1992 | 69 | 0.050 |
Why?
|
| India | 1 | 2012 | 13 | 0.050 |
Why?
|
| Osteoporosis | 1 | 2003 | 74 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 22 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2012 | 42 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 322 | 0.050 |
Why?
|
| Far East | 1 | 2011 | 6 | 0.050 |
Why?
|
| Diet | 1 | 1994 | 365 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 53 | 0.050 |
Why?
|
| Markov Chains | 1 | 2011 | 23 | 0.050 |
Why?
|
| Labor, Induced | 1 | 2011 | 6 | 0.050 |
Why?
|
| Multigene Family | 1 | 2011 | 7 | 0.050 |
Why?
|
| Genetic Carrier Screening | 1 | 2011 | 16 | 0.050 |
Why?
|
| North America | 1 | 2011 | 42 | 0.050 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2011 | 2 | 0.050 |
Why?
|
| Income | 2 | 2004 | 90 | 0.050 |
Why?
|
| Molecular Sequence Annotation | 1 | 2021 | 4 | 0.050 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1991 | 5 | 0.050 |
Why?
|
| Hydroxycholecalciferols | 1 | 2010 | 2 | 0.050 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2010 | 5 | 0.050 |
Why?
|
| Genetic Pleiotropy | 1 | 2020 | 9 | 0.050 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 7 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2011 | 218 | 0.050 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 187 | 0.050 |
Why?
|
| Seasons | 1 | 2010 | 102 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2010 | 35 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 80 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2010 | 87 | 0.040 |
Why?
|
| Congenital Abnormalities | 1 | 1990 | 26 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2010 | 46 | 0.040 |
Why?
|
| Vitamins | 1 | 2010 | 64 | 0.040 |
Why?
|
| Amenorrhea | 1 | 2010 | 3 | 0.040 |
Why?
|
| Cell Count | 1 | 2010 | 10 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2010 | 13 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2010 | 19 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 13 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 27 | 0.040 |
Why?
|
| Vitamin D | 1 | 2010 | 76 | 0.040 |
Why?
|
| Focus Groups | 1 | 2010 | 147 | 0.040 |
Why?
|
| Acculturation | 1 | 2009 | 20 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2009 | 7 | 0.040 |
Why?
|
| Introns | 1 | 2009 | 9 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2011 | 222 | 0.040 |
Why?
|
| Language | 1 | 2009 | 51 | 0.040 |
Why?
|
| Data Collection | 1 | 2010 | 256 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2009 | 46 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2009 | 297 | 0.040 |
Why?
|
| Glycemic Index | 1 | 2008 | 20 | 0.040 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2017 | 1 | 0.040 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2017 | 4 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2017 | 2 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 98 | 0.040 |
Why?
|
| Rectum | 2 | 2005 | 12 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 77 | 0.040 |
Why?
|
| Incontinence Pads | 1 | 2006 | 1 | 0.040 |
Why?
|
| Diapers, Adult | 1 | 2006 | 1 | 0.040 |
Why?
|
| Muscarinic Antagonists | 1 | 2006 | 5 | 0.030 |
Why?
|
| Coitus | 1 | 2006 | 4 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2007 | 127 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2006 | 77 | 0.030 |
Why?
|
| Sulfur Dioxide | 1 | 2016 | 1 | 0.030 |
Why?
|
| Gender Identity | 1 | 2016 | 36 | 0.030 |
Why?
|
| Indians, North American | 1 | 2006 | 49 | 0.030 |
Why?
|
| Anthropometry | 1 | 2006 | 66 | 0.030 |
Why?
|
| Probability | 1 | 2006 | 79 | 0.030 |
Why?
|
| Particulate Matter | 1 | 2016 | 29 | 0.030 |
Why?
|
| Progesterone | 1 | 2005 | 5 | 0.030 |
Why?
|
| Contraindications | 1 | 2005 | 14 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2005 | 9 | 0.030 |
Why?
|
| Linear Models | 1 | 2006 | 231 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2015 | 7 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2007 | 193 | 0.030 |
Why?
|
| Obstetric Surgical Procedures | 1 | 2005 | 1 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2005 | 41 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 45 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2005 | 8 | 0.030 |
Why?
|
| Information Systems | 1 | 2005 | 22 | 0.030 |
Why?
|
| Anesthetics | 1 | 1985 | 1 | 0.030 |
Why?
|
| Personnel, Hospital | 1 | 1985 | 9 | 0.030 |
Why?
|
| Menopause | 1 | 2005 | 68 | 0.030 |
Why?
|
| Maternal Age | 1 | 2005 | 77 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 2006 | 146 | 0.030 |
Why?
|
| Tobacco | 1 | 2014 | 14 | 0.030 |
Why?
|
| Gestational Age | 1 | 2005 | 111 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 25 | 0.030 |
Why?
|
| Epididymitis | 1 | 2014 | 1 | 0.030 |
Why?
|
| Gynecomastia | 1 | 2014 | 1 | 0.030 |
Why?
|
| Testis | 1 | 2014 | 2 | 0.030 |
Why?
|
| Klinefelter Syndrome | 1 | 2014 | 2 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2014 | 41 | 0.030 |
Why?
|
| Particle Size | 1 | 2002 | 4 | 0.030 |
Why?
|
| Occult Blood | 1 | 2004 | 153 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2002 | 35 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 2002 | 34 | 0.030 |
Why?
|
| Vagina | 1 | 2002 | 1 | 0.030 |
Why?
|
| Environmental Health | 1 | 2002 | 8 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2004 | 251 | 0.030 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2001 | 11 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2011 | 20 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2002 | 102 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 50 | 0.020 |
Why?
|
| Semen Analysis | 1 | 2010 | 4 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2011 | 164 | 0.020 |
Why?
|
| Medicare | 1 | 2001 | 202 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2000 | 15 | 0.020 |
Why?
|
| Models, Econometric | 1 | 2000 | 9 | 0.020 |
Why?
|
| Body Height | 1 | 2000 | 62 | 0.020 |
Why?
|
| Body Size | 1 | 2009 | 31 | 0.020 |
Why?
|
| Group Practice, Prepaid | 1 | 1998 | 7 | 0.020 |
Why?
|
| Death Certificates | 1 | 1998 | 19 | 0.020 |
Why?
|
| Research | 1 | 2008 | 64 | 0.020 |
Why?
|
| Fibroma | 1 | 1998 | 1 | 0.020 |
Why?
|
| Prolapse | 1 | 1998 | 1 | 0.020 |
Why?
|
| Endometriosis | 1 | 1998 | 4 | 0.020 |
Why?
|
| Uterine Diseases | 1 | 1998 | 5 | 0.020 |
Why?
|
| Marital Status | 1 | 1998 | 21 | 0.020 |
Why?
|
| Uterine Neoplasms | 1 | 1998 | 12 | 0.020 |
Why?
|
| Homes for the Aged | 1 | 1997 | 5 | 0.020 |
Why?
|
| Nursing Homes | 1 | 1997 | 8 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 1997 | 38 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 250 | 0.020 |
Why?
|
| Accidents, Occupational | 1 | 1985 | 6 | 0.020 |
Why?
|
| Federal Government | 1 | 1985 | 13 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 1994 | 45 | 0.020 |
Why?
|
| Vitamin A | 1 | 1994 | 14 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 1994 | 19 | 0.010 |
Why?
|
| Pulse | 1 | 1993 | 7 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1993 | 21 | 0.010 |
Why?
|
| Iron | 1 | 1993 | 16 | 0.010 |
Why?
|
| San Francisco | 1 | 1993 | 64 | 0.010 |
Why?
|
| Bias | 1 | 1993 | 102 | 0.010 |
Why?
|
| Microcephaly | 1 | 1990 | 3 | 0.010 |
Why?
|
| Cleft Palate | 1 | 1990 | 7 | 0.010 |
Why?
|
| Maternal Behavior | 1 | 1990 | 13 | 0.010 |
Why?
|
| Waste Products | 1 | 1985 | 1 | 0.010 |
Why?
|
| Gases | 1 | 1985 | 2 | 0.010 |
Why?
|
| Primary Prevention | 1 | 1985 | 73 | 0.010 |
Why?
|